Protocol summary
-
Study aim
-
Determination of the effect of hydro-alcoholic fumaria Parviflora extract on lipid profile, blood glucose indices, inflammatory factors, oxidative stress indices, in patients with type 2 diabetes under a low-calorie diet
-
Design
-
The study will be performed as a double-blind randomized controlled clinical trial on 66 patients aged 2 to 6 years with type 2 diabetes. The RAS program is used for randomization.
-
Settings and conduct
-
This study will be performed on patients with type 2 diabetes in the age range of 20-65 years in the endocrinology department of Imam Reza Hospital in Tabriz.
-
Participants/Inclusion and exclusion criteria
-
inclusion criteria : 1.Patients who agree to participate 2.Women aged 20 to 50 years and men 20 to 65 years, 3.BMI range between 25 and 40 kg /m2, 4.Using blood-sugar-lowering drugs. Exclusion criteria : 1. Reluctance to participate in the study, 2.Insulin injection, 3.Use any nutritional supplements such as omega-3.Supplements or supplements that have anti-inflammatory and antioxidant properties in the past 3 months or during the study, 4. Liver and kidney failure and thyroid disease, 5. Smoking and alcohol consumption, 6. Patients using NSAIDs, corticosteroids, thiazide, and second-generation antipsychotics, 7. Pregnancy and desire to conceive during the study, 8. Intestinal and gastrointestinal diseases and eating disorders
-
Intervention groups
-
The intervention group will receive 550 mg hydroalcoholic extract of Fumaria parviflora once a day and one hour after breakfast, and the other group will receive 550 mg placebo capsules (cornstarch) one hour after breakfast.
-
Main outcome variables
-
Evaluation of the effect of hydro-alcoholic extract of fumaria Parviflora on lipid profile, blood glucose indices, inflammatory factors, oxidative stress indices, in patients with type 2 diabetes mellitus of a low-calorie diet,(BCL-2،Nrf-2،BAX، Nf-kB،MCP-1) gene expression
General information
-
Reason for update
-
Adding new factors (gene expression)
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20130610013612N11
Registration date:
2021-09-23, 1400/07/01
Registration timing:
registered_while_recruiting
Last update:
2024-01-01, 1402/10/11
Update count:
1
-
Registration date
-
2021-09-23, 1400/07/01
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2021-08-23, 1400/06/01
-
Expected recruitment end date
-
2021-11-21, 1400/08/30
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
The effect of Fumaria Parviflora hydro-alcoholic extract on lipid profile, blood glucose indices, inflammatory factors, oxidative stress indices, and liver enzymes in patients with type 2 diabetes under a low-calorie diet
-
Public title
-
Effects of Fumaria Parviflora on diabetic patients
-
Purpose
-
Supportive
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients who agree to participate in the study
Women aged 20 to 50 years (non-menopausal) and men 20 to 65 years
BMI range between 25 and 40 kg /m2
; Having type 2 diabetes for at least 6 months while taking blood sugar-lowering drugs (metformin and thiazolidine )
Exclusion criteria:
Reluctance to participate in the study
Insulin injection
Use any nutritional supplements such as omega-3 supplements or supplements that have anti-inflammatory and antioxidant properties in the past 3 months or during the study
Liver and kidney failure and thyroid diseases
Smoking and alcohol consumption
Patients using NSAIDs, corticosteroids (prednisone, prednisolone, and hydrocortisone), thiazide (furosemide and hydrochlorothiazide), and second-generation antipsychotics (olanzapine and clozapine).
Pregnancy and desire to conceive during the study
Intestinal and gastrointestinal diseases and eating disorders
-
Age
-
From 20 years old to 65 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
-
Sample size
-
Target sample size:
66
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
In the current study, we will apply block randomization, one type of restricted randomization. Blocking is usually used to make a balance in the number of assigned samples to each studies group. This characteristic helps researchers in assigning an equal number of samples to each group, in cases that middle analyses are needed during the sampling process. The size of all the blocks is equal and in this two-group experiment, we will have 6 blocks (including 3 participants in the intervention group and 3 participants in the control group). Randomization tool also uses random allocation software that these random sequence generation software in addition to simple randomization are able to generate a random sequence by blocking method. For concealment, we use concealment allocation, which is the method used to execute a random sequence on study participants, so that the assigned group is not known before the individual is assigned. Using sealed opaque envelopes with random sequences (envelopes opaque, sealed, numbered sequentially) in which in this method each of the random sequences created is recorded on a card, and the cards inside the envelopes are placed in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the letter envelopes are glued and placed in a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes is opened in order and the assigned group of the participant is revealed.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
To reduce the bias or bias related to the intervention and the evaluation of outcomes, the double-blind method is used. In this way, the outcome can be measured objectively. In this method, the trial is planned in such a way that the participant and the researcher do not realize which of the two control or test groups they belong to.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2021-07-26, 1400/05/04
-
Ethics committee reference number
-
IR.TBZMED.REC.1400.378
Health conditions studied
1
-
Description of health condition studied
-
Type 2 diabetic patients
-
ICD-10 code
-
E08
-
ICD-10 code description
-
Diabetes mellitus due to underlying condition
Primary outcomes
1
-
Description
-
Total cholesterol
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
2
-
Description
-
Triglyceride
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
3
-
Description
-
high-density lipoprotein
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
4
-
Description
-
low-density lipoprotein
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
5
-
Description
-
atherogenic index of plasma
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
6
-
Description
-
Tumour Necrosis Factor alpha
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
7
-
Description
-
interleukin 6
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
8
-
Description
-
Intercellular Adhesion Molecule 1
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood Test
9
-
Description
-
Total antioxidant capacity
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood tests
10
-
Description
-
Malondialdehyde
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood tests
11
-
Description
-
glutathione peroxidase
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood tests
12
-
Description
-
Superoxide dismutase
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood tests
13
-
Description
-
Catalase
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Blood tests
14
-
Description
-
MCP-1gene expression
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Measurement of gene expression by RT-PCR method
15
-
Description
-
Nf-kB gene expression
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Measurement of gene expression by RT-PCR method
16
-
Description
-
BAX gene expression
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Measurement of gene expression by RT-PCR method
17
-
Description
-
Nrf-2 gene expression
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Measurement of gene expression by RT-PCR method
18
-
Description
-
BCL-2 gene expression
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Measurement of gene expression by RT-PCR method
Secondary outcomes
1
-
Description
-
Anthropometric indecs
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Body composition measuring device
2
-
Description
-
Antropometric indices (Weight, Height, BMI, Waist circumference, Hip circumference, Waist to Hip Ratio)
-
Timepoint
-
Baseline and 2 months after the intervention
-
Method of measurement
-
Physical exam
Intervention groups
1
-
Description
-
Intervention group: receives 550 mg daily of hydro-alcoholic extract of fumaria Parviflora for 2 months
-
Category
-
Treatment - Other
2
-
Description
-
Control group: receive 550 mg daily of placebo consisting of cornstarch for 2 months
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Tabriz University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
No - There is not a plan to make this available
-
Justification/reason for indecision/not sharing IPD
-
There is no more information
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Not applicable
-
Data Dictionary
-
Not applicable